Vest Financial LLC Acquires 11,171 Shares of LeMaitre Vascular, Inc. $LMAT

Vest Financial LLC increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 19.8% in the fourth quarter, HoldingsChannel reports. The firm owned 67,450 shares of the medical instruments supplier’s stock after buying an additional 11,171 shares during the period. Vest Financial LLC’s holdings in LeMaitre Vascular were worth $5,470,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of LMAT. SG Americas Securities LLC acquired a new stake in LeMaitre Vascular during the third quarter worth about $1,101,000. Congress Asset Management Co. grew its stake in shares of LeMaitre Vascular by 5.8% in the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock worth $59,392,000 after purchasing an additional 40,065 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in LeMaitre Vascular in the third quarter valued at $6,056,000. Public Sector Pension Investment Board lifted its holdings in LeMaitre Vascular by 15.8% during the 3rd quarter. Public Sector Pension Investment Board now owns 81,211 shares of the medical instruments supplier’s stock worth $7,107,000 after buying an additional 11,092 shares during the period. Finally, M&T Bank Corp grew its position in shares of LeMaitre Vascular by 2,240.5% in the 4th quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after buying an additional 381,061 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $112.39 on Wednesday. The stock has a fifty day moving average of $108.21 and a 200-day moving average of $93.68. The stock has a market cap of $2.57 billion, a PE ratio of 44.78, a price-to-earnings-growth ratio of 3.30 and a beta of 0.67. LeMaitre Vascular, Inc. has a fifty-two week low of $78.01 and a fifty-two week high of $118.01. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The company had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm’s revenue was up 15.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Equities research analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th were paid a $0.25 dividend. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 39.84%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Roth Mkm restated a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Wells Fargo & Company increased their price target on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a report on Thursday, February 26th. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Finally, Barrington Research lifted their price target on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $105.80.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the transaction, the insider directly owned 6,677 shares in the company, valued at $736,406.33. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David B. Roberts sold 8,464 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the transaction, the director owned 17,979 shares in the company, valued at $1,920,157.20. The trade was a 32.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 215,438 shares of company stock worth $23,062,911. Company insiders own 9.50% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.